NFIA
Basic information
Region (hg38): 1:60865259-61462788
Links
Phenotypes
GenCC
Source:
- chromosome 1p32-p31 deletion syndrome (Strong), mode of inheritance: AD
- brain malformations with or without urinary tract defects (Strong), mode of inheritance: AD
- chromosome 1p32-p31 deletion syndrome (Definitive), mode of inheritance: AD
- brain malformations with or without urinary tract defects (Definitive), mode of inheritance: AD
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Brain malformations with or without urinary tract defects | AD | Renal | The condition can include renal anomalies such as hydronephrosis and vesicoureteral reflux and awareness may allow early management, which may help prevent or manage renal sequelae | Neurologic; Renal | 17530927; 24462883; 27081522 |
ClinVar
This is a list of variants' phenotypes submitted to
- not provided (13 variants)
- Chromosome 1p32-p31 deletion syndrome (4 variants)
- Inborn genetic diseases (4 variants)
- Brain malformations with or without urinary tract defects (2 variants)
- NFIA-related disorder (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the NFIA gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 47 | 51 | ||||
missense | 65 | 75 | ||||
nonsense | 10 | 19 | ||||
start loss | 3 | |||||
frameshift | 10 | 17 | ||||
inframe indel | 5 | |||||
splice donor/acceptor (+/-2bp) | 4 | |||||
splice region | 9 | 20 | 5 | 34 | ||
non coding | 31 | 31 | 66 | |||
Total | 22 | 22 | 78 | 84 | 34 |
Variants in NFIA
This is a list of pathogenic ClinVar variants found in the NFIA region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
1-61077098-G-GAGGGGAGA | Benign (Aug 03, 2018) | |||
1-61077220-A-G | Benign (Jul 06, 2018) | |||
1-61077852-CT-C | Likely benign (Sep 08, 2019) | |||
1-61077852-C-CT | Benign (Jan 01, 2020) | |||
1-61081568-A-G | Likely benign (Aug 20, 2019) | |||
1-61081946-G-A | Uncertain significance (Jun 20, 2023) | |||
1-61081954-G-A | Inborn genetic diseases | Uncertain significance (Aug 09, 2021) | ||
1-61081983-G-A | NFIA-related disorder | Likely benign (Feb 28, 2023) | ||
1-61081990-C-T | Uncertain significance (Dec 15, 2022) | |||
1-61082009-C-A | Uncertain significance (Apr 04, 2023) | |||
1-61082038-C-T | Inborn genetic diseases | Uncertain significance (May 20, 2021) | ||
1-61082052-G-C | Chromosome 1p32-p31 deletion syndrome | Uncertain significance (Apr 05, 2020) | ||
1-61082594-CGCTG-C | Benign (May 18, 2021) | |||
1-61082672-TTC-T | Benign (Oct 21, 2019) | |||
1-61082762-C-A | Uncertain significance (Dec 15, 2022) | |||
1-61082792-A-C | Brain malformations with or without urinary tract defects | Uncertain significance (Mar 06, 2023) | ||
1-61082793-T-C | NFIA-related disorder | Pathogenic/Likely pathogenic (Jul 21, 2024) | ||
1-61082794-G-A | Pathogenic (Jun 28, 2023) | |||
1-61082806-C-G | Likely benign (Feb 04, 2022) | |||
1-61082806-C-T | Likely benign (Jan 06, 2023) | |||
1-61082806-CTG-C | NFIA-related disorder | Likely pathogenic (Sep 25, 2024) | ||
1-61082809-T-C | Likely benign (Dec 11, 2023) | |||
1-61082814-C-G | Inborn genetic diseases | Likely benign (Nov 27, 2023) | ||
1-61082816-C-T | Pathogenic (Jul 08, 2023) | |||
1-61082817-A-G | Uncertain significance (Jul 30, 2022) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
NFIA | protein_coding | protein_coding | ENST00000371189 | 12 | 597535 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
1.00 | 0.000407 | 0 | 0 | 0 | 0 | 0.00 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 3.23 | 158 | 321 | 0.492 | 0.0000181 | 3571 |
Missense in Polyphen | 44 | 137.52 | 0.31996 | 1539 | ||
Synonymous | -0.114 | 123 | 121 | 1.01 | 0.00000697 | 1123 |
Loss of Function | 4.85 | 2 | 31.2 | 0.0640 | 0.00000202 | 323 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.00 | 0.00 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.00 | 0.00 |
Finnish | 0.00 | 0.00 |
European (Non-Finnish) | 0.00 | 0.00 |
Middle Eastern | 0.00 | 0.00 |
South Asian | 0.00 | 0.00 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: Recognizes and binds the palindromic sequence 5'- TTGGCNNNNNGCCAA-3' present in viral and cellular promoters and in the origin of replication of adenovirus type 2. These proteins are individually capable of activating transcription and replication.;
- Disease
- DISEASE: Brain malformations with or without urinary tract defects (BRMUTD) [MIM:613735]: A syndrome characterized by corpus callosum hypoplasia or agenesis, hydrocephalus or ventricular enlargement, developmental delay, and urinary tract defects. {ECO:0000269|PubMed:24462883, ECO:0000269|PubMed:27081522}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
- Pathway
- miR-targeted genes in lymphocytes - TarBase;miR-targeted genes in muscle cell - TarBase;Gene expression (Transcription);RNA Polymerase III Transcription Termination;FOXA1 transcription factor network;RNA Polymerase III Abortive And Retractive Initiation;RNA Polymerase III Transcription
(Consensus)
Recessive Scores
- pRec
- 0.361
Intolerance Scores
- loftool
- 0.0782
- rvis_EVS
- -0.54
- rvis_percentile_EVS
- 20.26
Haploinsufficiency Scores
- pHI
- 0.350
- hipred
- Y
- hipred_score
- 0.773
- ghis
- 0.614
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.563
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Nfia
- Phenotype
- growth/size/body region phenotype; cellular phenotype; craniofacial phenotype; reproductive system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); renal/urinary system phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan);
Gene ontology
- Biological process
- negative regulation of transcription by RNA polymerase II;DNA replication;regulation of transcription, DNA-templated;viral genome replication;positive regulation of transcription by RNA polymerase II;synapse maturation;ureter development
- Cellular component
- nucleus;nucleoplasm;cell junction
- Molecular function
- RNA polymerase II proximal promoter sequence-specific DNA binding;DNA-binding transcription factor activity, RNA polymerase II-specific;DNA-binding transcription activator activity, RNA polymerase II-specific;chromatin binding;DNA-binding transcription factor activity;transcription factor binding